We are monitoring the impact of COVID-19 on Asia Pacific Urinary Tract Infections Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 4392
Share on
Share on

APAC Urinary Tract Infections Market Research Report – Segmented By Type Of Medication, Type Of Indication and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 4392
Pages: 145

APAC Urinary Tract Infections Market Size (2021 to 2026)

The size of the Urinary Tract Infections Market in the Asia Pacific was worth USD 4.13 billion in 2021 and estimated to be growing at a CAGR of 2.46%, to reach USD 4.66 billion by 2026.

The participants of the Asia Pacific urinary tract infection market are investing in their research and development departments to combine and launch new medications that are tailored to the needs of the Asian market. The APAC's urinary tract infections market is primarily expected to be driven by the Y-O-Y growth in the prevalence of hospital-acquired UTIs and technological advancements in testing instruments. Furthermore, excellent reimbursement conditions and illness management that are targeted boost market growth.

There has been an upsurge in the number of patients with urinary tract infections in the Asia Pacific. Urinary tract infections cause the second-largest patient pool on the planet. The market is expected to develop in response to rising prevalence and the desire for better treatment options. In addition, the market for urine infection testing will expand faster when new testing kits and technologies are introduced.

For companies in the Asia Pacific urinary tract infection treatment market, R&D in urinary tract infections is projected to offer lucrative growth prospects. In an intention-to-diagnose high-risk pediatric population, the Netherlands showed that urinary tract infections could be distinguished from non-urinary tract infections using volatile organic compound profiling and an electronic nose. Furthermore, the increased frequency of urinary tract infections in emerging nations is projected to help the market grow.

However, the introduction of new testing technologies into the market and rigorous regulatory standards are expected to limit the expansion of urinary tract infections in the APAC region. An increase hampers the market's growth in preference for alternative goods such as anti-infection catheters. Currently, the process of developing antibacterial medications and conducting clinical trials is a lengthy and complicated one. Furthermore, the lack of an ethical and scientific approach during these procedures is likely to limit the market's ability to grow as expected during the evaluation phase. The Asia Pacific market for urinary tract infection therapy is projected to be hampered by complex regulatory constraints.

This research report on the APAC urinary tract infections market has been segmented and sub-segmented into the following categories:

By Type of Medication:

  • Penicillin & Combinations 
    • Amoxicillin
    • Amoxicillin-Clavulanate Potassium combination
  • Quinolones             
    • Ciprofloxacin
    • Levofloxacin
    • Norfloxacin
    • Nalidixic Acid
  • Aminoglycoside-Antibodies             
    • Gentamicin
    • Amikacin
  • Cephalosporin       
    • Ceftriaxone
    • Cefixime
    • Cefuroxime
    • Cephalexin
  • Sulphonamides     
    • Sulfamethoxazole
    • Trimethoprim combination
  • Azoles & Amphotericin B  
  • Tetracycline            
    • Doxycycline
    • Nitrofurans
  • Nitrofurans 

By Type of Indication:

  • Uncomplicated UTI
  • Complicated UTI   
  • Recurring Complicated UTI               
  • Neurogenic Bladder Infection 

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, Asia Pacific is the fastest-growing region in the global market. Factors such as the increasing geriatric population and growing disposable incomes are expected to propel market growth in the region.

Low-income countries, such as those in the Asia Pacific, see an increase in the number of persons with diabetes. To assist these businesses with the necessary healthcare services and infrastructure, market participants are expanding their horizons to include worldwide acquisitions and mergers that benefit patients in this region.

KEY MARKET PLAYERS:

Companies playing an influential role in the Asia Pacific urinary tract infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type of Medication                 

                                5.1.1 Penicillin & Combinations 

                                                5.1.1.1 Amoxicillin

                                                5.1.1.2 Amoxicillin-Clavulanate Potassium combination

                                5.1.2 Quinolones             

                                                5.1.2.1 Ciprofloxacin

                                                5.1.2.2 Levofloxacin

                                                5.1.2.3 Norfloxacin

                                                5.1.2.4 Nalidixic Acid

                                5.1.3 Aminoglycoside-Antibodies             

                                                5.1.3.1 Gentamicin

                                                5.1.3.2 Amikacin

                                5.1.4 Cephalosporin       

                                                5.1.4.1 Ceftriaxone

                                                5.1.4.2 Cefixime

                                                5.1.4.3 Cefuroxime

                                                5.1.4.4 Cephalexin

                                5.1.5 Sulphonamides     

                                                5.1.5.1 Sulfamethoxazole

                                                5.1.5.2 Trimethoprim combination

                                5.1.6 Azoles & Amphotericin B  

                                5.1.7 Tetracycline            

                                                5.1.7.1 Doxycycline

                                                5.1.7.2 Nitrofurans

                                5.1.8 Nitrofurans             

                                5.1.9  Y-o-Y Growth Analysis, By Type of Medication       

                                5.1.10  Market Attractiveness Analysis, By Type of Medication   

                                5.1.11  Market Share Analysis, By Type of Medication    

                5.2 Type of Indication                    

                                5.2.1 Uncomplicated UTI              

                                5.2.2 Complicated UTI   

                                5.2.3 Recurring Complicated UTI               

                                5.2.4 Neurogenic Bladder Infection         

                                5.2.5 Y-o-Y Growth Analysis, By Type of Indication           

                                5.2.6 Market Attractiveness Analysis, By Type of Indication         

                                5.2.7 Market Share Analysis, By Type of Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Type of Medication

                                                6.1.3.2 By Type of Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Type of Medication

                                                6.1.4.2 By Type of Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Type of Medication

                                                6.1.5.2 By Type of Indication

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Pfizer, Inc.                   

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AstraZeneca plc                        

                8.3 Johnson & Johnson                 

                8.4 Novartis International AG.                   

                8.5 F. Hoffmann La Roche Ltd.                   

                8.6 Teva Pharmaceutical Industries Ltd.                

                8.7 Boehringer Ingelheim GmbH                              

                8.8 Cipla Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by type, packaging and meat type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the North america market; which includes broadly demographic, economic and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Urinary Tract Infections Market, By Type of Medication, From 2021 to 2026 (USD Million)
  2. Asia Pacific Penicillin & Combinations Market, By Region, From 2021 to 2026 (USD Million)
  3. Asia Pacific Quinolones Market, By Region, From 2021 to 2026 (USD Million)
  4. Asia Pacific Aminoglycoside-Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  5. Asia Pacific Cephalosporin Market, By Region, From 2021 to 2026 (USD Million)
  6. Asia Pacific Sulphonamides Market, By Region, From 2021 to 2026 (USD Million)
  7. Asia Pacific Azoles & Amphotericin B Market, By Region, From 2021 to 2026 (USD Million)
  8. Asia Pacific Tetracycline Market, By Region, From 2021 to 2026 (USD Million)
  9. Asia Pacific Nitrofurans Market, By Region, From 2021 to 2026 (USD Million)
  10. Asia Pacific Urinary Tract Infections Market, By Type of Indication, From 2021 to 2026 (USD Million)
  11. Asia Pacific Uncomplicated UTI Market, By Region, From 2021 to 2026 (USD Million)
  12. Asia Pacific Complicated UTI Market, By Region, From 2021 to 2026 (USD Million)
  13. Asia Pacific Recurring Complicated UTI Market, By Region, From 2021 to 2026 (USD Million)
  14. Asia Pacific Neurogenic Bladder Infection Market, By Region, From 2021 to 2026 (USD Million)
  15. Japan Urinary Tract Infections Market, By Type of Medication, From 2021 to 2026 (USD Million)
  16. Japan Urinary Tract Infections Market, By Type of Indication, From 2021 to 2026 (USD Million)
  17. China Urinary Tract Infections Market, By Type of Medication, From 2021 to 2026 (USD Million)
  18. China Urinary Tract Infections Market, By Type of Indication, From 2021 to 2026 (USD Million)
  19. India Urinary Tract Infections Market, By Type of Medication, From 2021 to 2026 (USD Million)
  20. India Urinary Tract Infections Market, By Type of Indication, From 2021 to 2026 (USD Million)
  21. Australia Urinary Tract Infections Market, By Type of Medication, From 2021 to 2026 (USD Million)
  22. Australia Urinary Tract Infections Market, By Type of Indication, From 2021 to 2026 (USD Million)
  23. South Korea Urinary Tract Infections Market, By Type of Medication, From 2021 to 2026 (USD Million)
  24. South Korea Urinary Tract Infections Market, By Type of Indication, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample